Radiopharm Theranostics Files 6-K Report

TL;DR

Radiopharm Theranostics filed a 6-K, confirming 20-F annual report filing and foreign private issuer status.

AI Summary

Radiopharm Theranostics Limited filed a Form 6-K on December 10, 2024, reporting information for the month of December 2024. The company is a foreign private issuer and is subject to reporting requirements under the Securities Exchange Act of 1934. The filing indicates that the company will file its annual reports under cover of Form 20-F.

Why It Matters

This filing provides routine updates for investors and the market regarding Radiopharm Theranostics' compliance and reporting status as a foreign private issuer.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new material financial or operational information.

Key Players & Entities

• Radiopharm Theranostics Limited (company) — Registrant
• 001-41621 (company) — Commission File Number
• 20241210 (date) — Filing Date
• December 2024 (date) — Reporting Period

FAQ

Filing Documents

• ea0224195-6k_radio.htm (6-K) — 13KB
• ea022419501ex99-1_radio.htm (EX-99.1) — 11KB
• ea022419501ex99-2_radio.htm (EX-99.2) — 64KB
• ex99-1_001.jpg (GRAPHIC) — 4KB
• ex99-2_001.jpg (GRAPHIC) — 4KB
• 0001213900-24-107117.txt ( ) — 101KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published two announcements (the “Public Notice”) to the Australian Securities Exchange on December 10, 2024 titled: - “Completion of preclinical data package for RAD 402” - “Change of Director’s Interest Notice PH” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Completion of preclinical data package for RAD 402 99.2 Change of Director’s Interest Notice PH 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: December 10, 2024 By: /s/ Phillip Hains Phillip Hains Company Secretary 3

View Full Filing

View this 6-K filing on SEC EDGAR